$10.6 M

APHB Mkt cap, 09-May-2019
AmpliPhi Biosciences Net income (Q1, 2020)-5.1 M
AmpliPhi Biosciences Cash, 31-Mar-202024.2 M
AmpliPhi Biosciences EV-11 M

AmpliPhi Biosciences Income Statement

Annual

USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

409.0k

Revenue growth, %

16%(45%)

R&D expense

5.8m4.0m5.7m2.9m4.9m9.8m

General and administrative expense

6.9m6.4m8.4m7.6m5.7m9.3m

Operating expense total

12.7m10.4m14.1m10.5m10.6m19.1m

EBIT

(14.1m)(10.2m)(23.4m)(16.2m)(12.5m)(19.8m)

EBIT margin, %

(3450%)

Interest expense

Interest income

6.0k96.0k

Pre tax profit

(589.0k)(19.4m)(14.1m)(12.4m)(19.5m)

Income tax expense

(73.0k)(556.0k)(1.3m)(328.0k)

Net Income

23.1m(516.0k)(18.8m)(12.8m)(12.1m)(19.5m)

AmpliPhi Biosciences Balance Sheet

Annual

USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

6.6m9.4m5.7m5.1m8.2m6.0m

Accounts Receivable

100.0k125.0k25.0k

Prepaid Expenses

339.0k521.0k253.0k251.0k622.0k

Current Assets

7.0m10.0m6.4m5.4m8.4m6.7m

PP&E

1.2m1.1m1.1m816.0k503.0k2.2m

Goodwill

7.6m7.6m7.6m3.5m

Total Assets

28.6m31.5m18.2m11.1m11.9m25.5m

Accounts Payable

1.2m1.5m1.7m578.0k729.0k547.0k

Dividends Payable

368.0k38.0k

Short-term debt

803.0k1.3m

Current Liabilities

1.9m2.4m3.6m2.0m2.6m4.9m

Long-term debt

803.0k1.6m

Total Debt

1.6m2.9m

Total Liabilities

23.2m6.9m8.5m3.4m3.4m10.9m

Common Stock

2.0m59.0k95.0k323.0k99.0k

Additional Paid-in Capital

363.5m375.2m390.9m401.8m414.5m172.0m

Retained Earnings

(362.0m)(362.5m)(381.4m)(394.2m)(406.3m)(157.5m)

Total Equity

3.4m12.7m9.7m7.7m8.5m14.6m

Debt to Equity Ratio

0.2 x

Debt to Assets Ratio

0.1 x

Financial Leverage

8.3 x2.5 x1.9 x1.4 x1.4 x1.7 x

Quarterly

USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Cash

16.4m12.6m9.8m16.6m14.4m11.7m6.2m7.1m4.0m2.2m9.0m7.7m8.2m5.8m4.5m5.5m13.2m8.7m24.2m

Accounts Receivable

12.0k136.0k27.0k40.0k14.0k18.0k24.0k15.0k

Prepaid Expenses

280.0k526.0k448.0k413.0k512.0k785.0k566.0k576.0k570.0k343.0k282.0k264.0k537.0k322.0k615.0k407.0k1.0m652.0k567.0k

Current Assets

16.7m13.2m10.3m17.0m14.9m12.6m6.8m7.7m4.6m2.6m9.2m8.0m8.7m6.1m5.1m5.9m14.2m9.9m25.8m

PP&E

356.0k1.1m1.3m1.2m1.1m1.2m1.2m1.2m1.2m982.0k909.0k847.0k727.0k678.0k591.0k420.0k3.4m2.5m2.0m

Goodwill

4.3m7.6m7.6m7.6m7.6m7.6m7.6m7.6m7.6m3.5m3.5m3.5m

Total Assets

34.4m34.7m31.9m38.6m36.4m34.1m28.3m29.3m26.0m14.3m15.1m13.8m14.4m11.7m10.6m9.6m34.9m29.3m44.1m

Accounts Payable

879.0k1.4m1.8m1.5m1.4m1.2m2.0m2.2m2.2m1.1m1.9m949.0k810.0k682.0k714.0k1.8m1.8m1.3m1.4m

Dividends Payable

131.0k368.0k368.0k970.0k953.0k38.0k38.0k38.0k

Short-term debt

598.0k606.0k305.0k1.4m

Current Liabilities

879.0k1.7m2.5m2.1m2.2m2.3m2.7m3.3m3.2m2.9m3.7m2.5m1.8m2.0m2.5m3.6m5.6m5.0m6.4m

Long-term debt

2.4m1.9m1.2m

Non-Current Liabilities

57.6m49.6m23.4m

Total Debt

101.0k598.0k606.0k305.0k2.4m1.9m2.6m

Total Liabilities

58.5m51.3m25.9m39.4m19.3m7.5m5.7m7.8m7.8m7.7m5.2m4.0m3.1m3.4m3.8m4.7m12.3m11.2m10.6m

Common Stock

1.8m1.9m1.9m2.8m57.0k59.0k59.0k111.0k111.0k165.0k85.0k93.0k165.0k165.0k165.0k328.0k99.0k99.0k186.0k

Preferred Stock

89.0k

Additional Paid-in Capital

367.0m360.9m362.0m370.6m378.8m375.9m374.5m390.9m390.0m391.1m400.9m401.5m408.5m408.6m408.7m414.6m168.5m171.0m195.9m

Retained Earnings

(394.8m)(382.5m)(361.3m)(376.5m)(365.7m)(360.3m)(365.6m)(369.5m)(371.9m)(384.6m)(391.1m)(391.9m)(397.3m)(400.4m)(402.0m)(409.9m)(146.0m)(152.9m)(162.6m)

Total Equity

(24.1m)(17.9m)4.4m(3.1m)13.1m15.7m8.9m21.5m18.2m6.6m9.9m9.8m11.3m8.3m6.9m5.0m22.6m18.1m33.5m

Debt to Equity Ratio

0 x0.1 x0.1 x0 x

Debt to Assets Ratio

0 x0 x0 x0 x

Financial Leverage

-1.4 x-1.9 x7.3 x-12.6 x2.8 x2.2 x3.2 x1.4 x1.4 x2.2 x1.5 x1.4 x1.3 x1.4 x1.5 x1.9 x1.5 x1.6 x1.3 x

AmpliPhi Biosciences Cash Flow

Annual

USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

23.1m(516.0k)(18.8m)(12.8m)(12.1m)(19.5m)

Depreciation and Amortization

158.0k330.0k369.0k374.0k389.0k1.4m

Accounts Receivable

(92.0k)(25.0k)100.0k

Accounts Payable

(977.0k)296.0k298.0k(838.0k)343.0k(1.4m)

Cash From Operating Activities

(12.6m)(9.8m)(10.6m)(9.2m)(9.4m)(15.6m)

Purchases of PP&E

(1.2m)(210.0k)(279.0k)(58.0k)(44.0k)(224.0k)

Cash From Investing Activities

(1.2m)(210.0k)(279.0k)(58.0k)(44.0k)2.9m

Dividends Paid

(80.0k)

Cash From Financing Activities

12.8m7.2m8.7m12.5m9.0m

Net Change in Cash

(13.8m)2.8m(3.7m)(579.0k)3.0m(3.7m)

AmpliPhi Biosciences Ratios

USDY, 2020

EV/CFO

2.6 x

Financial Leverage

1.3 x